Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total value of $859,716.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $31,045.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $1.05 during trading hours on Thursday, reaching $235.95. The stock had a trading volume of 391,825 shares, compared to its average volume of 439,210. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $261.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The business's fifty day moving average is $233.36 and its two-hundred day moving average is $228.79. The company has a market cap of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same period last year, the firm earned $2.67 EPS. The firm's revenue for the quarter was up 25.1% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. grew its position in United Therapeutics by 15.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 1,920 shares of the biotechnology company's stock worth $434,000 after acquiring an additional 260 shares during the last quarter. Asset Management One Co. Ltd. increased its holdings in shares of United Therapeutics by 2.8% in the third quarter. Asset Management One Co. Ltd. now owns 22,968 shares of the biotechnology company's stock valued at $5,188,000 after purchasing an additional 633 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of United Therapeutics by 8.2% during the third quarter. Handelsbanken Fonder AB now owns 7,900 shares of the biotechnology company's stock valued at $1,784,000 after acquiring an additional 600 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in United Therapeutics by 9.4% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 16,250 shares of the biotechnology company's stock worth $3,664,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Atwood & Palmer Inc. boosted its stake in shares of United Therapeutics by 1.0% in the 3rd quarter. Atwood & Palmer Inc. now owns 59,569 shares of the biotechnology company's stock valued at $13,455,000 after purchasing an additional 580 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. The Goldman Sachs Group upgraded United Therapeutics from a "sell" rating to a "neutral" rating and upped their price objective for the company from $213.00 to $215.00 in a report on Monday, February 12th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research note on Thursday, March 7th. Wedbush reaffirmed an "outperform" rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, April 11th. Finally, Leerink Partnrs reiterated an "outperform" rating on shares of United Therapeutics in a report on Monday, February 5th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.